Bristol-Myers Squibb

Yahoo Finance • 7 days ago

Bristol Myers Squibb Stock Earns 83 RS Rating

On Thursday, Bristol Myers Squibb stock got a positive adjustment to its Relative Strength (RS) Rating, from 80 to 83. IBD's proprietary rating tracks price performance with a 1 (worst) to 99 (best) score. Continue reading View comments... Full story

Yahoo Finance • 19 days ago

Dividend Stocks Are Primed for a Comeback in 2025

With highflying tech stocks looking expensive and bonds losing appeal​, ​some investors turn to dividend payers​. Continue reading View comments... Full story

Yahoo Finance • 2 months ago

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical... Full story

Yahoo Finance • 2 months ago

Jim Cramer on Bristol-Myers Squibb Company (BMY): ‘I Think It’s A Great Time To Consider Buying This One’

We recently compiled a list of the Jim Cramer's Exclusive List of 9 YEV Stocks.In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other YEV stocks in Jim Cramer's exclusive list... Full story

Yahoo Finance • 3 months ago

Bristol Myers' $10B Cancer Drug Opdivo Scores Expanded Use FDA Approval For Lung Cancer In Pre And Post-Surgery Setting

Bristol Myers' $10B Cancer Drug Opdivo Scores Expanded Use FDA Approval For Lung Cancer In Pre And Post-Surgery Setting On Thursday, the FDA approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) for resectable non-small cell... Full story

Yahoo Finance • 3 months ago

Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential

Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential On Thursday, the FDA approved Bristol Myers Squibb & Co’s (NYSE:BMY) Cobenfy (xanomeline and trospium chloride, KarXT),... Full story

Yahoo Finance • 3 months ago

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults

Product Image (Photo: Bristol Myers Squibb) Product Image (Photo: Bristol Myers Squibb) Gordon Lavigne, CEO, Schizophrenia & Psychosis Action Alliance Manufacturing B-Roll COBENFY™ (xanomeline and trospium chloride) Logo COBENFY represent... Full story

Yahoo Finance • 3 months ago

New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis

Final results from the DAYBREAK long-term extension study showed brain volume loss decreased during Phase 3 studies and was sustained with continuous Zeposia treatment for up to 5 years More than eight years of DAYBREAK data confirm estab... Full story

Yahoo Finance • 3 months ago

3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a Decade

With the major stock market indices up near all-time highs, finding stocks that pay satisfying dividend yields isn't nearly as easy as it used to be. Before you give up, though, consider Brookfield Renewable Partners(NYSE: BEP), Royalty Ph... Full story

Yahoo Finance • 3 months ago

Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024

PRINCETON, N.J., September 12, 2024--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) will announce results for the third quarter of 2024 on Thursday, October 31, 2024. Company executives will review financial results and address inquirie... Full story

Yahoo Finance • 4 months ago

Bristol Myers Squibb Announces Dividend

PRINCETON, N.J., September 10, 2024--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents ($0.60) per share on the $0.10 par value common stock of th... Full story

Yahoo Finance • 4 months ago

Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst

Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst HC Wainwright initiated coverage on Enliven Therapeutics, Inc. (NASDAQ:ELVN) and noted the company as an emerging biotech compa... Full story

Yahoo Finance • 4 months ago

2 No-Brainer Large-Cap Stocks to Buy With $500 Right Now

While a full-fledged, prolonged stock market correction could impact shares across a range of industries, investors with capital on hand can find that these periods present fortuitous opportunities to put cash to work. If you have the risk... Full story

Yahoo Finance • 4 months ago

As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors

As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors Wednesday, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) topline data for its Phase 2 clinical study of NBI-1117568... Full story

Yahoo Finance • 4 months ago

3 High-Yield Dividend Stocks With Payout Ratios Below 75%

High-yield dividend stocks can be enticing, with several academic studies showing that stocks yielding above 3% tend to outperform most other asset classes when held for 20 years or longer. However, dividend yield isn't the most important... Full story

Yahoo Finance • 4 months ago

2 Beaten-Down S&P 500 Dividend Stocks to Buy on the Dip and Hold Forever

The past year has been terrific for most stocks. The S&P 500 index rose 27.5% during the 12 months ended Aug. 26. It's always nice to see the value of your portfolio rise during a bull market, but it also makes it hard to find stocks to b... Full story

Yahoo Finance • 4 months ago

Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024

New analyses, including presentations on CAMZYOS® (mavacamten), ELIQUIS® (apixaban) and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases Not intended for UK and Ireland audiences PRI... Full story

Yahoo Finance • 4 months ago

Big Pharma: The government revealed its list of negotiated drug prices. Here are the reactions.

The Centers for Medicare and Medicaid Services (CMS) released its first-ever negotiated drug price list Thursday morning to a muted response on Wall Street. But industry and government officials weighed in— and didn't hold back. The power... Full story

Yahoo Finance • 4 months ago

US Drug Price Measure to Cut Costs by $7.5 Billion in 2026

(Bloomberg) -- The US government’s landmark drug price negotiations will save Americans $7.5 billion in its inaugural year, the Biden administration said, a first step toward driving down its world-leading pharmaceutical bill. Most Read f... Full story

Yahoo Finance • 4 months ago

Bristol Myers' German Partner Evotec Plans Layoffs, Cites 'Challenging Revenues, Profitability'

Bristol Myers' German Partner Evotec Plans Layoffs, Cites 'Challenging Revenues, Profitability' Wednesday, Evotec SE (NASDAQ:EVO) reported sales of $201.12 million (182.12 million euros), up from 170.28 million euros reported a year ago.... Full story